Morgan Stanley analyst Thomas Wrigglesworth maintained a Buy rating on Arkema today and set a price target of €78.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Wrigglesworth has given his Buy rating due to a combination of factors, even as he trims near‑term earnings forecasts. While acknowledging ongoing construction softness and FX pressure into 1H26, he highlights that capex has been scaled back, which helps protect free cash flow, and he expects only modest adjustments to EBITDA versus prior years.
He also points to management’s outlook for slight EBITDA growth at constant currency in FY26, supported by early signs of a construction trough in Europe and anticipated improvement in the U.S. thereafter. In addition, the portfolio reshuffle, which elevates low‑GWP refrigerants into Advanced Materials and concentrates more cyclical products in a separate segment, underlines a strategic tilt toward higher‑value, structurally growing end‑markets such as data centers and adhesives, reinforcing the Buy stance.
Wrigglesworth covers the Basic Materials sector, focusing on stocks such as Synthomer, Evonik, and Elkem ASA. According to TipRanks, Wrigglesworth has an average return of 10.1% and a 59.14% success rate on recommended stocks.